Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • Country/Region
  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • We guide you
    • Fertility
      • What to do if…
    • Prevent Inherited Diseases
      • Carrier Genetic Test
    • Worry-free Pregnancy
      • NACE
      • Prenatal Diagnostics
      • Newborn Health
  • Reproductive Health
    • Specialists
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • PGT-M
      • POC
      • SAT
      • Newborn Screening
    • Patients
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • PGT-M
      • SAT
      • POC
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Metabolic Precision Panel > Congenital Disorders of Glycosylation Precision Panel

Congenital Disorders of Glycosylation

Congenital Disorders of Glycosylation (CDG) are a group of rapidly expanding metabolic disorders that arise due to abnormal protein or lipid glycosylation. There are difficulties trying to diagnose them because they broadly affect many organs and functions, demonstrating a clinical heterogeneity. 
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Congenital Disorders of Glycosylation (CDG) are a group of rapidly expanding metabolic disorders that arise due to abnormal protein or lipid glycosylation. There are difficulties trying to diagnose them because they broadly affect many organs and functions, demonstrating a clinical heterogeneity. These phenotypically diverse disorders present as clinical syndromes affecting multiple systems including the central nervous system, muscle function, transport, regulation, immunity, endocrine system, and coagulation. Over 150 different CDGs have been and those affecting N-glycosylation are the most common type.  

  • The Igenomix Congenital Disorders of Glycosylation Precision Panel can be used to make an accurate and directed diagnosis ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.  

Indication

  • The Igenomix Congenital Disorders of Glycosylation Precision Panel is indicated for those patients with a clinical suspicion or diagnosis with or without the following manifestations: 
    • Low muscle tone or floppiness 
    • Failure to thrive 
    • Gross developmental delay 
    • Liver disease 
    • Abnormal bleeding or blood clotting 
    • Misaligned or crossed eyes 
    • Seizures 
    • Stroke-like episodes 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
  • Early initiation of treatment with a multidisciplinary team in the form of nutritional therapy, transplantation, activated sugars, gene therapy and pharmacological chaperones. 
  • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
  • Improvement of delineation of genotype-phenotype correlation given the clinical and genetically heterogenous profile of CDGs.  

Genes & Diseases

Methodology

References

See scientific referrals

Ng, B. G., & Freeze, H. H. (2018). Perspectives on Glycosylation and Its Congenital Disorders. Trends in genetics : TIG, 34(6), 466–476. https://doi.org/10.1016/j.tig.2018.03.002 

Scott, K., Gadomski, T., Kozicz, T., & Morava, E. (2014). Congenital disorders of glycosylation: new defects and still counting. Journal of inherited metabolic disease, 37(4), 609–617. https://doi.org/10.1007/s10545-014-9720-9 

Verheijen, J., Tahata, S., Kozicz, T., Witters, P., & Morava, E. (2020). Therapeutic approaches in Congenital Disorders of Glycosylation (CDG) involving N-linked glycosylation: an update. Genetics in medicine : official journal of the American College of Medical Genetics, 22(2), 268–279. https://doi.org/10.1038/s41436-019-0647-2 

Bogdańska, A., & Tylki-Szymańska, A. (2020). Wrodzone zaburzenia glikozylacji białek – stale powiększająca się grupa chorób metabolicznych [Congenital disorders of glycosylation – constantly growing group of metabolic diseases]. Postepy biochemii, 66(3), 213–228. https://doi.org/10.18388/pb.2020_345 

Gilfix B. M. (2019). Congenital disorders of glycosylation and the challenge of rare diseases. Human mutation, 40(8), 1010–1012. https://doi.org/10.1002/humu.23829 

Jaeken J. (2013). Congenital disorders of glycosylation. Handbook of clinical neurology, 113, 1737–1743. https://doi.org/10.1016/B978-0-444-59565-2.00044-7 

descargar

Detail description

Download

Request Information


WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
Country/Region

[2021] © Igenomix Privacy policy Quality policy Legal note Cookies policyNews and Press

Request Information


  • We guide you
    • Fertility
      • What to do if…
    • Prevent Inherited Diseases
      • Carrier Genetic Test
    • Worry-free Pregnancy
      • NACE
      • Prenatal Diagnostics
      • Newborn Health
  • Reproductive Health
    • Specialists
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • PGT-M
      • POC
      • SAT
      • Newborn Screening
    • Patients
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • PGT-M
      • SAT
      • POC
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

International
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

More information about our Cookie Policy